Related Experiment Video

Updated: Mar 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis

Z Meng1, X Ma1,2, J Du1,2

  • 1Department of Diabetes Complications and Metabolism, Beckman Research Institute of City of Hope, Duarte, CA, USA.

Oncogene
|November 8, 2016
PubMed

Insights

Calcium/calmodulin-dependent protein kinase II gamma isoform (CAMK2γ) antagonizes hepatocellular carcinoma (HCC) progression by suppressing mechanistic target of rapamycin complex 1 (mTORC1) activation, offering potential therapeutic targets for this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a deadly cancer with limited effective treatments.
  • Kinase signaling dysregulation is implicated in HCC development.
  • Identifying novel therapeutic targets is crucial for HCC treatment.

Purpose of the Study:

  • To identify kinases regulating gene expression in HCC using bioinformatic approaches.
  • To investigate the role of calcium/calmodulin-dependent protein kinases II gamma isoform (CAMK2γ) in hepatocarcinogenesis.
  • To elucidate the molecular mechanism by which CAMK2γ influences HCC progression.

Main Methods:

  • Bioinformatic analysis of human HCCs and murine HCC models.
  • Utilizing CAMK2γ knockout (CAMK2γ-/-) mice and wild-type controls.
  • Investigating the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, including IRS1/AKT signaling.

Main Results:

  • CAMK2γ deletion significantly enhanced chemical-induced hepatocarcinogenesis in mice.
  • Loss of CAMK2γ potentiated hepatic mTORC1 activation, leading to hepatocyte hyperproliferation.
  • CAMK2γ suppressed growth factor- or insulin-induced mTORC1 activation by inhibiting IRS1/AKT signaling.
  • Rapamycin treatment attenuated hepatocyte proliferation in CAMK2γ-/- livers.

Conclusions:

  • CAMK2γ plays a protective role against hepatocarcinogenesis.
  • CAMK2γ antagonizes mTORC1 activation, thereby suppressing hepatocyte proliferation.
  • CAMK2γ inhibition of IRS1/AKT signaling is a key mechanism in its tumor-suppressive function.
  • Targeting the CAMK2γ-mTORC1 axis may offer a novel therapeutic strategy for HCC.

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K